Company profile
Hypha Labs, Inc.
OTC: FUNI · Healthcare · Medical - Diagnostics & Research
#766 of 1,418 Healthcare companies by revenue53rd-percentile growth
EA Score
35DFH 20DQ 47GM 57SS 37
v0.1 · 65/100 weight · provisional
↑ disclosure history, growth stability · ↓ Piotroski F, return on assets
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$3.1M
Employees
5
as of 2026-08-24
Market cap
$1.5M
as of 2026-08-24
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.7M$2.7M2022
Net income-$3.1M-$3.1M2025
Operating income-$3.0M-$3.0M2025
Total assets$409.2k$409.2k2025
Liabilities$2.5M$2.5M2025
Equity-$2.4M-$2.4M2025
Revenue trend
FY2015 – FY2022 · USD
FY15
FY16
FY18
FY18
FY19
FY20
FY21
FY22
Revenue by segment
Filed disclosures · FY2015
By product
Microscopy96%
Cannabis4%
By geography
Not disclosed.
The read
What is Hypha Labs, Inc.’s revenue?
Hypha Labs, Inc. booked $2.7M in FY2022 revenue, growing 7.8% year over year — about the middle of the pack among Healthcare companies we track, at a -114.9% net margin.
Peers · Healthcare
Medical Supply International USA, Inc.——RxElite, Inc.——Absci Corporation47DQHSLab, Inc.70BInnovative Eyewear, Inc.45DInfinity Pharmaceuticals, Inc.——Neighbors
Clark →Key facts
CEOA. Stone Douglass
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersLas Vegas, NV
ExchangeOTC: FUNI
Employees5
IPO date2012-08-13
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.